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Abstract
The glucose-insulin system is a challenging process to model due to the feedback
mechanisms present, hence the implementation of a model-based approach to
the system is an on-going and challenging research area. A new approach is
proposed here which provides an effective way of characterising glycaemic regu-
lation. The resulting model is built on the premise that there are three phases
of insulin secretion, similar to those seen in a proportional-integral-derivative
(PID) type controller used in engineering control problems. The model relates
these three phases to a biological understanding of the system, as well as the
logical premise that the homeostatic mechanisms will maintain very tight con-
trol of the system. It includes states for insulin, glucose, insulin action and a
state to simulate an integral function of glucose.
Structural identifiability analysis was performed on the model to determine
whether a unique set of parameter values could be identidied from the available
observations, which should permit meaningful conclusions to be drawn from pa-
rameter estimation. Although two parameters - glucose production rate and the
proportional control coefficient - were found to be unidentifiable, the former is
not a concern as this is known to be impossible to measure without a tracer ex-
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periment, and the latter can be easily estimated from other means. Subsequent
parameter estimation using Intravenous Glucose Tolerance Test (IVGTT) and
hyperglycaemic clamp data was performed and subsequent model simulations
have shown good agreement with respect to these real data.
Keywords: PID control, Mathematical models, Diabetes, Insulin, Glucose,
Structural Identifiability
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1. Introduction
Over recent decades much research has been devoted to the development of
models that characterise the interaction between glucose and insulin. Probably
the most widely known, accepted and applied model in this field is the Minimal
Model (and its variants) introduced by Bergman et al. [1]. Previously, mod-
els had been large and very complex in structure, whereas the Minimal Model
is, as the name suggests, minimal in terms of its structure and the number
of key system parameters that it includes. In particular, the Minimal Model
also includes in its structure a very important parameter representing insulin
sensitivity, which is a measure of how much glucose is removed from the blood
per unit of insulin. In certain situations the Minimal Model is a very useful
tool, however in others it does not necessarily meet expectations as shown by
De Gaetano et al.[2]. For example, insulin secretion with the minimal model is
stopped after the glucose level falls below a certain threshold, making it invalid
once the system has returned to a steady state.
More recently, a Beta Cell Mass Model has been developed by Topp et al.[3].
Unlike the Minimal Model, it is concerned with a long-term view of glucose-
insulin dynamics and includes an additional compartment to represent β-cell
mass. While this model appears to predict long-term aspects of the system and
disease progression well, it lacks a representation of insulin delay and insulin se-
cretion is geared to a steady state, which makes it far less useful for short-term
modelling.
Jauslin/Silber[4] have also developed an alternative model to characterise glucose-
insulin interaction. The Jauslin/Silber model follows standard pharmacokinetic
structures and attempts to be applicable to both Oral Glucose Tolerance Tests
(OGTTs) and Intravenous Glucose Tolerance Tests (IVGTTs) in both healthy
and type 2 diabetic patients. Using this model and the data collected to look
at 24 hour profiles of these subjects, aspects of the insulin effect compartment
have been incorporated into the design of the model presented here.
The glucose-insulin homeostatic system is an important control mechanism in
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both animals and man. If the glucose level is elevated above normal (hypergly-
caemia), its toxic effect can damage blood vessels, nerves and other important
body systems. When the blood glucose level is raised, the endothelial cells that
line the blood vessels absorb more glucose than normal, leading the blood vessels
to grow thicker and weaker which reduces blood flow throughout the body. This
can cause retinopathy leading to vision loss, neuropathy (loss of sensation) and,
in severe cases, amputation is necessary. Other potential complications include
nephropathy, which may require dialysis or kidney transplant, heart attacks,
strokes and muscle wasting. If the glucose level falls too low (hypoglycaemia),
there is insufficient energy to sustain normal function of the central nervous sys-
tem, which may result in coma and even death. For a full review of the eitology
of type 2 diabetes see Haffner [5].
To prevent serious damage such as that detailed above, the glucose-insulin home-
ostatic system is crucial and is therefore normally very finely controlled. It is
critically damped or even very slightly over-damped, keeping it close to a steady
state or a fixed point with little overshoot and returning high levels of glucose
rapidly back to the fixed point show by Bolie[6].
2. The Model
2.1. Modelling Approach
The aim of the modelling approach undertaken here was to create a unified,
robust model for the glucose-insulin system that would:
• Be applicable to a variety of different clinical tests, such as an IVGTT and
hyperglycaemic or euglycaemic clamps.
• Be stable, robust (e.g. not having an output which increases exponentially
over time) and ensure that meaningful results would be produced even
with large variations between subjects.
• Give realistic results, even with extremes of data, such as high insulin
resistance in cases where the subject is progressing towards type 2 dia-
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betes or in an animal model such as a Zucker rat model shown in [7].
Another example would be high fasted glucose levels where a subject has
uncontrolled type 2 diabetes.
It is desirable to have a model that is minimal in form, but it must still contain
sufficient structural parameters to accurately model the physical system. It
must therefore contain only necessary components and have only one set of
parameters per individual, but provide enough flexibility to explain variation
between subjects. In order to ensure that the model remains valid in extreme
situations, it should adhere to biological theory in such a way that parameter
difference between subjects represents different physical attributes. The model
should use familiar concepts so it is easily understood and can be applied by
both the mathematical/engineering community and the pre-clinical and clinical
bioscience community.
2.2. Model Concept
Various engineering disciplines require a very fine level of control to be main-
tained over systems - chemical synthesis processes, for example, may require fine
control over water temperature. Control could be achieved using a thermostat,
where a heater is switched on or off depending on the water temperature, how-
ever this would not give sufficiently accurate control for some situations, such
as distilling in [8], so engineers have developed more accurate controllers specif-
ically for this task. The human body requires similar levels of fine control for
its homeostatic mechanisms. It is a logical conclusion that both human design
and the process of evolution may have developed an appropriate solution in the
form of a similar controller.
A PID controller has been used in many engineering applications, see for
example [9]. It consists of three terms to control the system output. In a
normal PID controller, a configured set-point is compared to the output of the
system. The difference between these is the error signal. The PID controller uses
this error signal to try and make the system return to the set-point, where the
error signal would be zero. The PID controller produces three control signals:
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proportional, which is a multiple of the error signal, integral, the area under the
curve of the error signal, and differential, the rate of change of the error signal.
A PID controller has also been used as a method of controlling glucose levels in
type 1 diabetics, i.e. those diabetics who do not secrete any insulin. There have
been attempts to produce an artifical pancreas using continous glucose monitors
with a PID controller to regulate the infusion of insulin[10, 11, 12, 13, 14, 15].
To the authors’ knowledge, there has been no attempt to use a PID controller
as an analogy for β-cells in an attempt to explain how they function. The
controller can be shown to fit with the way that the beta cells in the pancreas
secrete insulin:
Proportional:
• In mathematical terms, this means that for every unit of plasma glucose,
a fixed amount of insulin is released by the pancreas. See Figure 3.
• This part of the controller simulates the secretion in basal conditions. The
proportional aspect maintains a basal level of glucose in the system and a
basal level of insulin to match.
• In biological terms, this means that glucose enters the beta cell which, via
glycolysis and oxidative phosphorylation, increases the level of ATP [16].
In the proportional controller analogy, the ATP predominantly promotes
granules of pro-insulin towards the membrane. See Figure 1.
Integral:
• In mathematical terms, this is the area under the curve (AUC) of the
glucose concentration.
• This part simulates the second phase insulin response: the shoulder of
insulin observed after an IVGTT.
• In biological terms, this is similar to the proportional control and means
that an accumulation of glucose causes the beta cells to secrete an addi-
tional quantity of insulin, possibly from the readily releasable pool [17].
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This represents the amount of insulin required to remove the glucose after
a meal, sugar intake or clinical challenge.
Derivative:
• In mathematical terms, this is the rate of change of glucose level.
• This part represents the first phase insulin response: the relatively high
amount of insulin that is seen initially in experiments such as IVGTT.
• In biological terms, this could mean that the docked insulin granules on the
cell membrane are predominantly released in a rapid response to a large
increase in the amount of glucose present. It gives a measured response
to sudden, large changes in concentration of glucose but has little effect
when levels rise slowly.
<< Figure 1 in here >>
The model presented here is split into three sections: Insulin Secretion (I(t)
and Ii(t)), Delayed Insulin Action (Ia(t)), and Net Difference in Glucose G(t)).
2.3. Insulin Secretion
The basal levels of glucose and insulin are not fixed points in the biological
mechanism. Instead, they are determined by the effect they have on each other
in their steady states. The Beta Cell Mass Model [3] has been developed in this
way; the basal levels of each are not defined, but are determined by the combi-
nation of parameters used. The model shows what can happen in the system if
a reduction of insulin sensitivity occurs.
This is a central point for model design as it is vital in ensuring that the param-
eters have relevance to the underlying biology. A classic PID controller could
be related to a biological system by saying the set point was the basal glucose
level and the error signal was the basal level minus the current level. Although
having a set point for basal levels of glucose would produce similar results, it
would not be a mechanistic representation of the underlying biology. In reality,
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this is not quite a valid analogy as a biological system does not have a defined set
point, so the challenge is to design a model with similar terms to those present
in a PID Controller without a set point.
The terms in the PID controller relate to the biological process as follows:
Proportional: kpG(t)
This term simply creates the basal level under static conditions. The pro-
portional secretion rate is produced by taking the level present in the glucose
compartment.
Integral: kiIi(t)
This is non-trivial as the area under the glucose curve will increase over time,
causing the system to become unstable. Hence the integral function must decay
over time when the system tends towards steady state. It is created by taking
the concentration in the glucose compartment as the rate of change of a virtual
compartment Ii(t).
dIi(t)
dt
= G(t)− kiirIi(t) (1)
Derivative: kd
dG(t)
dx
This is a rate of change, so the absolute value of the glucose does not matter.
This is simply taken as the rate of change of glucose, and is incorporated in the
following equation:
dI(t)
dt
= kpG(t) + kiIi(t) + kd
dG(t)
dt
− iirI(t) (2)
2.4. Delayed Insulin Action
There is a delay between insulin secretion and its action lowering glucose.
There are several sources that state that this delay could be caused by factors
including, but not limited to, interstitial action sites and saturation of certain
pathways [18, 19, 20]. This delay has been incorporated into other models and is
well-validated [1, 4]The duration of the delay is relatively short in clinical terms
(of the order of a few minutes), however compared to the time-scales considered
in this model it is significant and therefore important to include.
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In the tests shown below, the IVGTT and the hyperglycaemic clamp both start
with an elevated level of glucose. As insulin and glucose are both drivers of
glucose disposal rate, as illustrated by equation 4, it is difficult to distinguish
whether the high glucose disposal rate is due to the elevated glucose level, the
corresponding elevated insulin level or both. Therefore, from the tests below,
it is difficult to establish whether a delay in insulin action is present; however,
based on evidence from the literature that a delay should be present, it has been
decided that a delay should be incorporated into the model.
In order to include this delay in the model, an insulin action compartment,
Ia(t), was incorporated. This compartment is the same as the interstitial com-
partment in the Minimal Model, but is rearranged here for easy interpretation
ofthe parameters:
dIa
dt
= I(t)− kiarIa(t) (3)
where kiar is the clearance rate from the insulin action compartment.
2.5. Net Difference in Glucose
The glucose compartment has a number of inputs (which are impossible to
determine without tracer experiments, [21]) and a number of outputs. The
relative rates of supply and dispersal of glucose in this compartment determine
the basal level. This is modelled in a clear manner in the Beta Cell Mass Model
[3]; it has an appearance rate that is made up of all unknown appearance rates
and all the disposal rates that can be calculated. The appearance rate cannot be
established without tracer experiments, however as appearance rate is related
to the amount of glucose present, obtaining an absolute value is unimportant.
Insulin has an effect on both the production rate of glucose and its disposal
rate, however it is impossible to distinguish and quantify the effect on each as
the end result is the same.
This provides us with three key parameters (shown in equation (4)):
• Rate of glucose production (which is fixed), gp.
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• Glucose Effectiveness, which describes the insulin-independent removal of
glucose (i.e. the removal of glucose based on glucose concentration alone),
gr.
• Insulin Sensitivity, which is the net effect of insulin on lowering the glucose
level, ksi.
dG(t)
dt
= gp − (gr + ksi.Ia(t)).G(t) (4)
Figure (2) summarises the model.
<< Figure 2 in here>>
<< Figure 3 in here >>
3. Steady States
As mentioned above, unlike some previous models this system does not have
steady states dependent on parameters such as glucose and insulin basal levels.
The system should tend to steady states based on the system parameters and
the feedback components present.
At steady state, nothing is changing hence the derivative term in the model is
zero. With a classic PID controller, there is an error signal entering the con-
troller; however this is not the case with this system as there is no “set point”
to derive an error signal from. The integral control is therefore required to in-
troduce decay. This makes the calculations slightly complex as the steady state
for this parameter is non-zero.
From the system equations (1)-(4) the steady states can be calculated alge-
braically, for example from equation (1) we have:
Iiss =
Gss
kiir
(5)
Adding in the proportional control, the steady state for insulin becomes:
Iss =
kiIiss + kpGss
kir
(6)
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From equation 3 the steady state for insulin action is given by:
Iass =
Iss
kiar
(7)
and the resulting steady state for glucose is given by:
Gss =
gp
gr + ksi · Iass (8)
These can be calculated from the system equations algebraically.
4. Structural Identifiability
The problem with using a simplistic model, such as a 2-compartment model,
is that it does not capture all the dynamics of the system - such as the variable
insulin dynamics created by rapid changes in glucose [22] - and hence is not an
accurate representation. On the other hand, a pathway model would require a
larger number of parameters which would allow different combinations of val-
ues to produce the same system output. As a variety of different parameter
combinations could be used to fit the same data, it would be impossible to tell
which was actually correct; this would make it impossible to validate the model
and therefore render it practically useless. The solution is to create a model
which is a balance between these two approaches, by using not only parameters
that can be uniquely identified but also a mechanistic structure that adequately
describes the physical process and dynamics that are observed. This creates a
need for a test to validate the model by ensuring that all parameters can be
uniquely identified.
Such a test exists in the form of structural identifiability analysis. A system
is said to be structurally globally identifiable if, with infinite, noise-free ob-
servations, there is only one possible set of parameters that can produce the
output. Although real data will be neither infinite nor noise-free, structural
identifiability in this form is a step on the way to approaching numerical iden-
tifiability or parameter estimation with greater confidence. Glucose and insulin
measurements can be taken for this model. The insulin integral compartment
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is just a representation of an integral function. The model was treated as an
uncontrolled non-linear system. All the parameters including initial conditions
were considered unknown. There are various techniques for performing a struc-
tural identifiability analysis, [23]. The Lie-symmetry approach by Yates et al.
[24] has been applied to the model introduced here, as other techniques such
as the Taylor series approach could not yield a solution due to computational
difficulties. The analysis is presented in the appendix and was performed using
Mathematica 7 [25]. Mathematica was selected for the analysis as it is excellent
for complex symbolic manipulation and performing the analysis by hand would
be time-consuming and error-prone. System Observability is a prerequisite for
the Lie-symmetry technique, so the Observability Rank Criterion was applied to
the model with observations of G(t) and I(t), which showed it to be observable.
Application of this approach concluded that the model is at least locally iden-
tifiable (as global identifiability cannot be established with the Lie-symmetry
approach) when two parameters were known: gp, which represents glucose pro-
duction, and kp, the proportional insulin secretion function; other insulin secre-
tion terms could be used instead, however it is easier to consider the proportional
control as it can be calculated at basal states.
This leads to issues with the following parameters:
gp - This represents the amount of glucose entering the system, which is typ-
ically unknown. It can be set to an estimate, perhaps obtained from a tracer
experiment, as the clearance is fractional so an exact value is not necessary.
kp - The proportional insulin secretion function is more difficult to estimate,
however assuming that that the integral component is negligible at steady state
a rough estimate for kp can be obtained using the known insulin clearance with
this expression which has been derived from the steady state.
kp ≈ irIbasal
Gbasal
(9)
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5. Parameter Estimation
The data used for parameter estimation were rat data (IVGTT and hy-
perglycaemic clamps) from AstraZeneca and data obtained from an IVGTT
experiment on a healthy human and previously used with the Minimal Model
and the program MINMOD by [26]. The data were fitted using acslX 2.5 [27]
and a PKPD toolkit developed at AstraZeneca. Fitting was performed using a
Quasi-Newton optimisation algorithm and the built-in Gear’s Stiff Integration
algorithm. This was performed on a standard PC (Windows XP SP3, 2GB
RAM, 1.66 GHz Intel Core 2 Duo) within a few seconds. See Figures 4-6 and
Table 2 for the fitted parameters. The description of the parameters is in Table
1. The parameter fitting and subsequent model simulation provide good agree-
ment compared to experimental data, and similar parameter values can be used
across animals (noting that the animals in the clamp and the IVGTT are dif-
ferent hence the slight difference in values). An important point to note is that
kd is not well-fitted with respect to the hyperglycaemic clamp experiment due
to the lack of data at the start of the clamp. All other parameters estimates are
within 20% of their correct value with 95% confidence. The parameter values
have been adjusted slightly as without all the components of the controller, the
model does not control the glucose levels in the simulation.
<< Table 1 in here>>
<< Table 2 in here>>
<< Figure 4 in here>>
<< Figure 5 in here>>
<< Figure 6 in here>>
6. Discussion
This paper has presented a novel glucose-insulin model which has been devel-
oped on mechanistic biological principles. The model has four key parameters
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(kp, ki, kd, kir) derived from the PID controller type terms incorporated in the
model structure for glucose-stimulated insulin secretion (GSIS) and may help
to identify and differentiate between the effect of drugs or incretins such as GIP
and GLP-1 by showing an increase in one or more of the PID parameters. This
allows clearer observation of external influences (such as drugs or disease) af-
fecting mechanisms in the pancreas. It can also help identify which part of the
glucose-insulin homeostasis is impaired, providing a better understanding of the
mechanism of insulin resistance in type 2 diabetics.
The insulin sensitivity (ksi) and glucose removal rate (gr) are clearly defined,
making it easy to identify the difference between subjects.
This paper introduces a new concept for the glucose-insulin model, in particular
the PID approach to insulin secretion terms. Other models have included insulin
secretion terms; for example the Minimal Model [1], although this does not have
a first-phase insulin secretion term, and the DIST and DISTq models [28, 29],
though these use larger numbers of parameters than the model presented here.
Insulin sensitivity in this model was based on the interstitial insulin compart-
ment from the Minimal Model, however there are valid alternative methods to
calculate insulin sensivity[30].
Unlike many other models, this model was not developed for a specific test, such
as IVGTT, or hyperglycaemic clamp, and was designed to be a fully-coupled
system to ensure it was physiologically representative of the glucose-insulin feed-
back system. This should ensure its applicability in a variety of circumstances
and attempts at applying this model to tests such as OGTT (Oral Glucose Tol-
erance Test) and diurnal variation due to feeds are currently being investigated.
There are other factors affecting the system which could be taken into account
in the modelling. Insulin clearance is known to affect different situations such
as OGTTs, IVGTTs and fasted conditions seen by [31]; including a C-peptide
model [32] would help to solve this problem. Incretins and lipids, which also
play a role in insulin secretion, are not taken into account in this model. Addi-
tionally, disease modelling - such as depletion of insulin capacity - is not taken
into account here, however it may help quantify certain aspects of disease where
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other models may fail. For instance, if the first phase of insulin secretion was
decreased, this would be reflected in the derivative parameter (kd). These are
all factors that are to be included in future work and development of the model.
Models and control systems for managing glucose homeostatics are becoming
increasingly important with current developments in constant glucose moni-
toring ([33]) in conjunction with the use of insulin pumps. A PID controller
has been used to attempt to manage glucose with an artifical pancreas by
[10, 11, 12, 13, 14, 15], an approach which seems to be supported by this work.
It is interesting to note that when a PID controller has been used in an artifical
pancreas in practice it caused glucose levels to drop too low, which meant that
another attempt was made using just a PI controller (i.e. one with no differential
term) however the differential term was determined well in the paper [34].
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Appendix:Mathematica Code
Load the Lie group package in to Mathematica. (The output from the package
is suppressed)
Needs["SymmetryAnalysis`IntroToSymmetry`"];
Defines the differential equations:
inputequation1="D[x1[t],t]-p[4]+ (p5[t] +(p6[t] *x4[t]))*x1[t]";
inputequation2="D[x2[t],t] -p[7]*x1[t] +p10[t]*x2[t] - x3[t]*p8[t]- p9[t]*D[x1[t],t]";
inputequation3="D[x3[t],t]-x1[t]+ p11[t]*x3[t]";
inputequation4="D[x4[t],t]-x2[t]+p12[t]*x4[t]";
inputequation5="D[p4[t],t]";
inputequation6="D[p5[t],t]";
inputequation7="D[p6[t],t]";
inputequation8="D[p7[t],t]";
inputequation9="D[p8[t],t]";
inputequation10="D[p9[t],t]";
inputequation11="D[p10[t],t]";
inputequation12="D[p11[t],t]";
inputequation13="D[p12[t],t]";
Associated substitution rules are also defined to aid the symmetry package:
rulesarray={"D[x1[t],t]->-(-p4[t]+ (p5[t] +(p6[t] *x4[t]))*x1[t])",
"D[x2[t],t] ->-(-p7[t]*x1[t] +p10[t]*x2[t] - x3[t]*p8[t]- p9[t]*x1[t])",
"D[x3[t],t]->-(-x1[t]+ p11[t]*x3[t])",
"D[x4[t],t]->x2[t]-p12[t]*x4[t]","D[p4[t],t]->0",
"D[p5[t],t]->0",
"D[p6[t],t]->0",
"D[p7[t],t]->0",
"D[p8[t],t]->0",
"D[p9[t],t]->0",
"D[p10[t],t]->0",
"D[p11[t],t]->0",
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"D[p12[t],t]->0"};
Independent and dependent variables are defined:
independentvariables={"t"};
dependentvariables={"x1","x2","x3","x4","p4","p5","p6",
"p7" ,"p8","p9","p10","p11","p12"};
Package parameters are defined:
frozennames = {""};
p = 1;
r = 0;
xseon = 1;
internalrules = 1;
The Lie symmetries are derived for the differential equations:
FindDeterminingEquations[independentvariables,dependentvariables, frozennames,
p, r, xseon, inputequation1, rulesarray, internalrules];
zdeterminingequations1 = zdeterminingequations;
Repeated for ever inputequation and then joined:
zdeterminingequations = Join[zdeterminingequations1, zdeterminingequations2,
zdeterminingequations3, zdeterminingequations4, zdeterminingequations5,
zdeterminingequations6, zdeterminingequations7, zdeterminingequations8,
zdeterminingequations9, zdeterminingequations10, zdeterminingequations11,
zdeterminingequations12, zdeterminingequations13];
The determining equations are solved up to symmetries of polynomial order 1:
SolveDeterminingEquations[independentvariables,dependentvariables,r,
xseon,zdeterminingequations,1]
The symmetries of the differentual equations are displayed:
TableForm[xsefunctions]
xse1=a10 + a12*z10 + a13*z11 + a14*z12 + a15*z13 +
a16*z14 + a111*z6 + a112*z7 + a113*z8 + a114*z9
TableForm[etafunctions]
eta1=0
eta2=0
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eta3=0
eta4=0
eta5=b50 + b52*z10 + b53*z11 + b54*z12 + b55*z13 + b56*z14
+ b511*z6 + b512*z7 + b513*z8 + b514*z9 eta6=0
eta7=0
eta8=b80 + b82*z10 + b83*z11 + b84*z12 + b85*z13
+ b86*z14 + b811*z6 + b812*z7 + b813*z8 + b814*z9
eta9=0
eta10=0
eta11=0
eta12=0
eta13=0
The conditions are that the perturbation on time, xse1, must be zero. Only
eta5 and eta8 are non-zero which means they are unidentifiable. eta5 relates to
p4 which is gp and eta8 relates to p7 which is kd. See structural identifiability
section in the main part of the paper for an explanation of how these parameters
are dealt with.
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Figure Captions
Figure 1:Diagram of the beta-cell to show the elements of it that relate to the
terms in the PID controller.
Figure 2:Schematic diagram of the PID model of the glucose and insulin system.
Figure 3:The elements of the PID controller split up to show their individual
influence on insulin secretion in the model.
Figure 4:Parameter fit of a human IVGTT using the PID model with data from
[26].
Figure 5:Parameter fit of a rat IVGTT using the PID model.
Figure 6:Parameter fit of a rat hyperglycaemic clamp using the PID model.
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Table Captions
Table 1: Description of the parameters in PID model.
Table 2: Fitted parameter estimates in the PID model using data from As-
traZeneca and [26].
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Parameter Units Description
gr min
−1
Glucose Effectiveness, insulin-independent glucose
removal (most of the glucose removal in this test is
determined by insulin hence the insensitivity)
gp mmol l
−1 min−1 Glucose production rate
ksi ml ng
−1 Insulin sensitivity, insulin-dependent glucose removal
kp µg mmol
−1 min−1 Proportional parameter for PID model
ki µg mmol
−1 min−2 Integral parameter for PID model
kd µg mmol
−1 Differential parameter for PID model
kir min
−1 Insulin clearance
kiir min
−1 Integral clearance rate, to simulate integral function
kiar min
−1 Insulin action increase rate, to delay insulin action
G0 mmol l
−1 Starting glucose
I0 µg l
−1 Starting insulin
Ia0 mmol l
−1 min Starting insulin action (non-sensitive parameter)
Ii0 µg l
−1 min Starting insulin integral (non-sensitive parameter)
Table 1: Description of the parameters in the PID model.
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Parameter
Human Han Wistar Han Wistar
Units
IVGTT IVGTT Hyperglycaemic Clamp
gr 0.00159 0.0438 0.0413 min
−1
gp [3] 0.033 0.033 0.033 mmol l
−1 min−1
ksi 0.00231 0.00105 0.00107 ml ng
−1
kp (Equation 9) 0.0275 0.009274 0.00896 µg mmol
−1 min−1
ki 0.00000158 0.000872 0.000256 µg mmol
−1 min−2
kd 0.268 0.450 0.455 µg mmol
−1
kir 0.169 0.351 0.118 min
−1
kiir 1.38E-19 1.38E-19 1.38E-19 min
−1
kiar 0.114 0.0296 0.258 min
−1
G0 5.11 5.8 6.7 mmol l
−1
I0 0.379 0.879 0.348 µg l
−1
Ia0 0 0 0 mmol l
−1 min
Ii0 0 0 0 µg l
−1 min
Table 2: Fitted parameter estimates in the PID model using data from AstraZeneca and [26].
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Figure 1: Diagram of the beta-cell to show the elements of it that relate to the terms in the
PID controller.
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Figure 2: Schematic diagram of the PID model of the glucose and insulin system.
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Figure 3: The elements of the PID controller split up to show their individual influence on
insulin secretion in the model.
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Figure 4: Parameter fit of a human IVGTT using the PID model with data from [26].
Figure 5: Parameter fit of a rat IVGTT using the PID model.
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Figure 6: Parameter fit of a rat hyperglycaemic clamp using the PID model.
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